dc.contributor.author |
Karunasinghe, N |
en |
dc.contributor.author |
Wang, A |
en |
dc.contributor.author |
Vaidyanathan, Venkatesh |
en |
dc.contributor.author |
Ferguson, LR |
en |
dc.coverage.spatial |
Queenstown, New Zealand |
en |
dc.date.accessioned |
2019-09-30T20:38:21Z |
en |
dc.date.issued |
2018-10-24 |
en |
dc.identifier.citation |
New Zealand Oncology Conference. 24 Oct 2018 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/48139 |
en |
dc.description.abstract |
Supplemented selenium for prostate health varies with genetic polymorphisms and dietary mineral interaction Dr. Nishi Karunasinghe, Dr. Alice Wang, Venkatesh Vaidyanathan and Prof. Lynnette R Feguson The most recent Cochrane systematic review on selenium (Se) for preventing cancer concludes that the risk ratio for prostate cancer incidence or mortality has no strong negative association with Se exposure (1). Meanwhile, in New Zealand we are leading the global incidence of prostate cancer (2). We also have a disparity of high-risk prostate cancer diagnosis compared to that of the US (3). Our prostate cancer patients record lower serum Se levels (101.2 ± 1.01ng/ml) at diagnosis (4) compared to those from the US (135+/-21ng/ml for European Americans and 132+/-25ng/ml for African Americans (5)). Our men with no known prostate cancers show a serum Se level of 112.9 ± 1.01 ng/ml while the European Americans and African Americans record serum Se levels of 140+/-28 and 134+/-21 ng/ml respectively (5). We have previously recorded that Se benefits for health vary with age, BMI, lifestyle factors, genetics and dietary folate and methionine levels (6). Here we present results of benefit variability of supplemented Se (200μg/d for six months) in regulating prostate health marker the serum prostate specific- antigen levels in a healthy cohort of Auckland men. We record that PSA regulating benefits vary with polymorphisms in genes encoding antioxidant and androgen pathway proteins as well as interaction with dietary minerals. 1. Vinceti M, Filippini T, Del Giovane C et al. (2018) Selenium for preventing cancer. Cochrane Database Syst Rev 1, CD005195. 2. Ferlay J, Shin HR, Bray F et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127, 2893-2917. 3. Karunasinghe N. ea (2017) Abstract-Who suffers most in a low level PSA screening system? A comparison of prostate cancer cohorts from New Zealand and USA? Australia New Zealand Urogenital and Prostate Cancer Trials Group, Annual Scientific Meeting. 4. Karunasinghe N, Han DY, Goudie M et al. (2013) Prostate Disease Risk Factors among a New Zealand Cohort. J Nutrigenet Nutrigenomics 5, 339-351. 5. Vogt TM, Ziegler RG, Graubard BI et al. (2003) Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Cancer 103, 664-670. 6. Karunasinghe N, Zhu S, Ferguson LR (2016) Benefits of Selenium Supplementation on Leukocyte DNA Integrity Interact with Dietary Micronutrients: A Short Communication. Nutrients 8. |
en |
dc.description.uri |
http://www.nzsoncology.org.nz/conference/programme |
en |
dc.relation.ispartof |
New Zealand Oncology Conference |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Supplemented selenium for prostate health varies with genetic polymorphisms and dietary mineral interaction-- proof of concept! |
en |
dc.type |
Conference Poster |
en |
dc.rights.holder |
Copyright: The authors |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.elements-id |
777377 |
en |
pubs.org-id |
Academic Services |
en |
pubs.org-id |
Examinations |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
pubs.record-created-at-source-date |
2019-07-29 |
en |